LoadingLoadingLoadingNet selling: insiders sold $6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Alger
$48.9M
added
Sells/Trims (2)
Citadel
$78.2M
trimmed
Point72
$44.4M
trimmed
Top-trader positions in RGEN could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 28, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.45 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 20, 2026
EPS expected
$0.41 to $0.48
Revenue expected
17 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 28, 2026 | $0.54 / $0.45Yahoo Finance | +20.38% beat | $204.1M No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $0.48 / $0.39Yahoo Finance | +22.87% beat | $194.3M No estimate | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $0.49 / $0.44Yahoo Finance | +10.38% beat | $197.9M No estimate | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $0.46 / $0.42Yahoo Finance | +10.56% beat | $188.8M No estimate | Unavailable |
| Jun 30, 2025 | Jul 29, 2025 | $0.37 / $0.39Alpha Vantage | -5.13% miss | $182.4M No estimate | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $0.39 / $0.35Alpha Vantage | +11.43% beat | $169.2M No estimate | Unavailable |
| Dec 31, 2024 | Feb 20, 2025 | $0.44 / $0.42Alpha Vantage | +4.99% beat | $167.5M No estimate | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | -$0.01 / $0.33Alpha Vantage | -103.55% miss | $154.9M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $188.8M | $197.9M | $194.3M | $204.1M |
| Cost of what it sold | $88.3M | $104.5M | $95.8M | $95.8M |
| Gross profit | $100.5M | $93.4M | $98.5M | $108.4M |
| What it spent | ||||
| Research and development | $14.2M | $12.2M | $14.5M | $14.4M |
| Sales and admin | $73.7M | $86.0M | $76.5M | $76.6M |
| Other operating costs | -$4.1M | -$23.3M | -$10.5M | $5.4M |
| Total operating expenses | $83.7M | $74.9M | $80.5M | $96.4M |
| What was left | ||||
| Operating profit | $16.8M | $18.6M | $18.0M | $11.9M |
| Interest on debt | $27.4M | $5.9M | $6.0M | $17.2M |
| Profit before tax | $17.1M | $19.1M | $1.8M | $14.2M |
| Tax | $2.2M | $5.8M | -$6.6M | $9.1M |
| Net profit | $14.9M | $13.3M | $8.3M | $5.0M |
| EBITDA | $46.9M | $49.6M | $32.3M | $45.9M |
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Repligen Corp (RGEN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 85/100
Leans bearishOct 16Repligen Corporation (RGEN) Stock Forecasts
NeutralOct 15Repligen to Report Third Quarter 2026 Financial Results
NeutralOct 14A company behind systems used to make biological drugs will discuss results Oct. 27. Repligen's call starts at 8 a.m.
NeutralOct 14Repligen to Report Third Quarter 2026 Financial Results
NeutralOct 13Repligen to Report Third Quarter 2026 Financial Results
NeutralOct 13Weekly Recap: BioLife cash-and-stock deal and Q3 2026 outlook details
Leans bullishOct 12Form 144 REPLIGEN CORP For: 12 October By Investing.com
NeutralOct 1220 macro signals shaping RGEN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
